focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
What impact will the tie up of open orphan offering Quotients antibody test in UK, testing starts in next few weeks, test has 100% sensitivity (ability to detect COVID-19 antibodies) and 99.8% specificity (ability to rule out the presence of COVID-19 antibodies).
Quotient have other distributors in other markets too
Is this webinar only available to sharesoc members? Will the transcript be released afterwards?
SP up7% in first 3 mins
This is from Mercola a very unreliable source https://quackwatch.org/11Ind/mercola/
Listen to about 11 mins in. Talk of spinning off imutex stake as separate listed company with existing shareholders getting one for one shares
https://m.soundcloud.com/doc-h-4/6-5-20-interview-cathal-friel
Assuming positive news in the Lancet about the Malaria Vaccine "in the next couple of weeks", what impact do people think it will have on the SP?
If the Trial was a flop would they go for publication in the Lancet?
The first study is ready to publish data which has been passed hence the announcement of the lancet paper https://clinicaltrials.gov/ct2/show/results/NCT03055000
The second study is on-going until 2021 https://clinicaltrials.gov/ct2/show/results/NCT04009824
Why was this interview taken down? Also made private on YouTube, what did they let slip?
https://www.proactiveinvestors.co.uk/companies/news/908750/open-orphan-plc-s-cathal-friel-details-merger-with--sleeping-giant--hvivo-908750.html
Why was this interview taken down? Also made private on YouTube, what did they let slip?
https://www.proactiveinvestors.co.uk/companies/news/908750/open-orphan-plc-s-cathal-friel-details-merger-with--sleeping-giant--hvivo-908750.html
Development Assets
Imutex Limited ("Imutex")
hVIVO is a minority partner in Imutex, a joint venture with SEEK Group to support the development upside of new vaccine candidates. The joint venture was formed in 2016 under the previous management of hVIVO and represented a departure from the historical and now current strategy of services provision for third party client product development. These vaccines remain in clinical development and accordingly there is no guarantee of future revenue. The potential total costs and time to commercialisation remain unknown at this stage. The lead asset, FLU-v, has achieved positive Phase II data and is regarded as a licensable asset. Imutex continues to explore options for the FLU-v vaccine programme and has engaged in multiple business development discussions, some of which are still active. Imutex is also establishing schedules for meetings with key regulatory authorities, FDA and EMEA, where it hopes to gain further insight into some of the key areas of interest expressed by potential partners.
The historical cost of investment in Imutex is held on the balance sheet however it is not utilised in the hVIVO Group's operations. hVIVO contributes management oversight over the future direction of the development of the vaccine candidates, but makes no capital investment to the ongoing development work undertaken by the joint venture. The hVIVO management expect to review the carrying value and consider any requirement for impairment following the year end.
I asked if they are pursuing funding from UNISEC or NIAID, This was the response...
Thank you for your enquiry.
The Board of Imutex is exploring strategic alternatives with regards to both assets (FLU-v & AGS-v) and continues to explore a number of options to enable the continued development of the FLU-v vaccine. Any material information regarding discussions or about the Imutex assets will be announced as appropriate.
Kind regards.
Fleur